Silver Point Capital’s PDL BioPharma, Inc. PDLI Stock Holding History

Silver Point Capital’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-23,783,273	Closed	-$58.7M	–	15
2020 Q4	$58.7M	Buy	23,783,273 +17,359,273	+270%	+$42.3M	6.82%	3
2020 Q3	$20.2M	Buy	6,424,000 +1,524,000	+31%	+$4.87M	2.47%	5
2020 Q2	$14.3M	Hold	4,900,000	–	–	2.01%	5
2020 Q1	$13.8M	Buy	+4,900,000	New	+$15.8M	1.62%	12

Other funds holding PDLI

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Public Employees Retirement Association of Colorado Denver, Colorado $25.5B AUM 28.85% 1-Year Est. Return

Silver Point Capital's PDLI Position: Q1 2021 in Review

Silver Point Capital sold out of PDL BioPharma, Inc. (PDLI) in Q1 2021, closing a stake of 23,783,273 shares — an estimated $58.7M sold.

Silver Point Capital first reported a position in PDLI in Q1 2020 and held it in 4 quarters. The position peaked at $58.7M in Q4 2020. 11 funds tracked by Wall St. Rank hold PDLI as of Q1 2021.

Silver Point Capital reported no remaining PDL BioPharma, Inc. position as of Q1 2021 after selling out during the quarter.
Silver Point Capital sold 23,783,273 PDL BioPharma, Inc. shares in Q1 2021, an estimated $58.7M.
Silver Point Capital first reported a position in PDL BioPharma, Inc. in Q1 2020 and held it in 4 quarters.
Silver Point Capital's PDL BioPharma, Inc. position peaked at $58.7M in Q4 2020.
11 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2021.

Based on Silver Point Capital's 13F filing for Q1 2021, filed 17 May 2021.